Completed PHASE3 INTERVENTIONAL 2-arm NCT00372216

CIPAMI-Study: Clopidogrel Administered Prehospital to Improve Primary PCI in Patients With Acute Myocardial Infarction

Sponsor: Bristol-Myers Squibb

Interventions Clopidogrel (Iscover/Plavix)

Updated 6 times since 2017 Last updated: Nov 18, 2010 Started: Oct 31, 2006 Primary completion: Oct 31, 2009 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Myocardial Infarction and is currently completed. Bristol-Myers Squibb leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
Sanofi
Stiftung Institut fuer Herzinfarktforschung

Data source: Stiftung Institut fuer Herzinfarktforschung

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bad Nauheim, Germany , Berlin, Germany , Brandenburg, Germany , Celle, Germany , Darmstadt, Germany , Frankfurt am Main, Germany , Giessen, Germany , Heppenheim an der Bergstrasse, Germany , Holzminden, Germany , Innsbruck, Austria and 10 more locations